Imaging required to monitor effects of new Alzheimer’s drug could inhibit its uptake
Although providers are optimistic about the potential of a new treatment for Alzheimer’s, some are concerned that the burden of monitoring the drug’s effect on patients could limit its uptake. In January 2023, Eisai/Biogen’s Leqembi—a drug shown to reduce clinical decline by up to 27% in patients with Alzheimer’s—was given accelerated approval by the U.S. Food and Drug […]
Eisai’s Alzheimer’s drug Leqembi gaining ground with US neurologists, but most waiting on full approval: Spherix
U.S. neurologists are “cautiously optimistic” about using Eisai’s Leqembi in Alzheimer’s disease as concerns about safety and the need for the FDA’s full green light for the drug remain high barriers to uptake. That’s according to a new survey and report out by drug launch analyst Spherix Global Insights, which in March asked 73 neurologists working in […]
At Fifteen Months Post-Launch, AbbVie’s Qulipta Outperforms Pfizer’s Nurtec ODT on Perceived Overall Efficacy in the Preventive Migraine Space, According to Spherix Global Insights
Use of Qulipta as a preventive migraine treatment still trails Nurtec ODT, but future projections have the brands’ use on par. Exton, PA., March 16, 2023 – Spherix Global Insights recently released data from their Launch Dynamix™: Qulipta for Migraine Prevention (US) deep dive study tracking the launch of AbbVie’s Qulipta for the preventive treatment […]
New Spherix Data in Alzheimer’s Disease Reveals High Potential for Emerging Anti-Amyloid Therapies from Genentech, Biogen/Eisai, and Eli Lilly, As Well As Novo Nordisk’s Semaglutide
New Spherix Data in Alzheimer’s Disease Reveals High Potential for Emerging Anti-Amyloid Therapies from Genentech, Biogen/Eisai, and Eli Lilly, As Well As Novo Nordisk’s Semaglutide Differentiation amongst these pipeline agents will hinge on ease of access, easy-to-use companion diagnostics, and safety EXTON, Pa., July 2022 – Despite multiple high-profile trial failures in early Alzheimer’s disease […]
Biohaven’s Nurtec ODT and AbbVie’s Qulipta Emerging as the Top Two Contenders in the Preventive Migraine Space, According to Spherix Global Insights
Growth of newer market entrants resulting in relatively flat projected share for Eli Lilly’s Emgality, Teva’s Ajovy, and Amgen’s Aimovig EXTON, Pa., June 10, 2022 /PRNewswire – According to the latest deep dive report included in Spherix’s Launch Dynamix™: Qulipta for Migraine Prevention (US) service, surveyed neurologists and migraine specialists report high satisfaction with AbbVie’s Qulipta […]
Report: Tecfidera, Aubagio Preferred RRMS Treatments in Canada
From: Multiple Sclerosis News Today By: Marisa Wexler MS Tecfidera (dimethyl fumarate) and Aubagio (teriflunomide) are the preferred disease-modifying treatments for managing relapsing-remitting multiple sclerosis (RRMS) in Canada, according to a report from Spherix Global Insights. The report was part of Spherix’s RealTime Dynamix: Multiple Sclerosis (Canada) service, which collects data on market trends of MS treatments in Canada by […]
The Very Slow Roll of Biogen’s Aduhelm: Neurologists Weigh in on Patients, Practices and Payments Amid Ongoing Media Storm
From: Endpoints News By: Beth Snyder Bulik Five months after the approval of Biogen’s Aduhelm, the bad news just keeps piling up for the Alzheimer’s drug. The confirmation yesterday of a Biogen investigation into the death of trial participant is the latest setback, but it adds to a laundry list of ongoing woes including […]
Ocrevus Still Top Therapy for Progressive MS Forms, Report Finds
From: Multiple Sclerosis News Today By: Marisa Wexler MS Ocrevus (ocrelizumab) continues to be the most commonly prescribed therapy for progressive forms of multiple sclerosis (MS), including primary progressive MS (PPMS) and secondary progressive MS (SPMS), according to an analysis from the market intelligence firm Spherix Global Insights. However, other therapies are “gaining traction” among SPMS patients, the report finds…(read more)
Genentech’s Trailblazing Ocrevus Maintains Leading Position in the Progressive Multiple Sclerosis Space, But Emerging Bruton’s Tyrosine Kinase Inhibitors Could Threaten Its Long-Term Dominance
New patient-level data show that newer market entrants, such as BMS’ Zeposia and Novartis’ Kesimpta, are gaining traction in the US treatment algorithm EXTON, Pa., November 4, 2021/PRNewswire/ – Although the population of multiple sclerosis (MS) patients with progressive disease remains underserved, several recent approvals for relapsing MS (RMS), which includes active secondary progressive […]
Post-Launch Insights Point to Four Key Factors That Could Drive Future Use of Biogen/Eisai’s Aduhelm in Alzheimer’s Disease
What the Aduhelm manufacturers and others with agents in the pipeline can learn from early launch metrics EXTON, Pa., October 7, 2021 /PRNewswire/ — At three months post-launch, the high expectations for Biogen/Eisai’s Aduhelm in Alzheimer’s disease have not quite materialized. Neurologist-reported patient share for the drug, as well as the percentage of neurologists who have ever […]
